BSBE(SZ:300406) Xin Lang Zheng Quan·2025-10-21 01:21Group 1 - The core viewpoint of the news is that Jiukang Bio's stock performance and financing activities indicate a mixed outlook, with a slight increase in stock price but a significant net financing outflow on October 20 [1] - On October 20, Jiukang Bio's stock rose by 0.53%, with a trading volume of 31.75 million yuan. The net financing buy was -4.14 million yuan, indicating more financing repayment than new purchases [1] - As of October 20, Jiukang Bio's total financing and securities lending balance was 182 million yuan, with a financing balance of 181 million yuan, accounting for 2.34% of the circulating market value, which is below the 50th percentile level over the past year [1] Group 2 - As of June 30, Jiukang Bio had 18,500 shareholders, an increase of 21.57% from the previous period, while the average circulating shares per person decreased by 17.73% to 22,920 shares [2] - For the first half of 2025, Jiukang Bio reported operating revenue of 668 million yuan, a year-on-year decrease of 18.67%, and a net profit attributable to shareholders of 175 million yuan, down 30.01% year-on-year [2] - Since its A-share listing, Jiukang Bio has distributed a total of 1.214 billion yuan in dividends, with 585 million yuan distributed in the last three years [3]